Nebula Genomics AI Visibility Market Strategy Report - DNA Testing Kits

Answer Capsule

Nebula Genomics holds a small but real position in AI-generated DNA testing recommendations, with 16.52% valid recommendation coverage in October 2026. The brand is visible but under-recommended relative to its presence, and it carries the largest baseline decline in the category, down 10.80 percentage points from July 2026. Its clearest win is a rank-one rate that rose even as overall coverage fell, and its clearest weakness is a shrinking mention presence that is eroding faster than its recommendation placement. The biggest opportunity sits in converting its existing whole-genome sequencing authority into stronger recommendation-stage visibility across the platforms where it still appears.

Who This Report Is For

This report is for Nebula Genomics leadership, category strategists, and marketing teams evaluating how AI search and chat surfaces present the brand against the broader DNA testing kit market.

Report Card

Executive Summary

Nebula Genomics is visible in AI-generated DNA testing recommendations but is not converting that visibility into recommendation-stage strength at the rate its category position would suggest. The brand recorded 126 mentions across 563 qualified observations in October 2026, a raw mention presence rate of 22.38%, but only 93 of those mentions converted into valid recommendations, a valid recommendation coverage of 16.52%. That gap between presence and recommendation is the defining feature of the brand's current AI visibility profile.

The brand's sentiment profile is positive. Of its 126 mentions, 97 were positive, 27 were neutral, and 2 were negative, producing a net sentiment score of 0.754. That places Nebula Genomics in positive framing territory, but positive framing alone is not producing recommendation conversion at scale.

The strongest platform signal for Nebula Genomics is Gemini, where the brand recorded a valid recommendation coverage of 33.77% and a rank-one rate of 3.90%, both the highest of any tracked platform. Google AI Mode also shows meaningful presence at 10.08% valid recommendation coverage. The weakest platform signal is Perplexity, where the brand recorded a valid recommendation coverage of 6.90% and no rank-one placements.

The clearest gap is between the brand's presence and its recommendation conversion. Nebula Genomics appears in 22.38% of qualified observations but is only recommended in 16.52%, and it appears in the top three in just 7.10% of observations. The brand is being mentioned as context more often than it is being recommended as a choice.

The category context matters here. AncestryDNA leads at 73.18% valid recommendation coverage, and 23andMe follows at 67.32%. Nebula Genomics sits sixth in the category, behind Living DNA at 17.23%, and its 10.80-point decline from July 2026 is the largest baseline movement of any tracked brand. The brand has declined in each of the three months since the July baseline.

The most consequential finding in the current data is the presence of three critical factual inconsistencies about whether Nebula Genomics is still operating. Gemini and Copilot provided directly conflicting answers to the same high-intent questions, with Gemini describing the brand as active and Copilot stating the brand shut down in 2025. This inconsistency sits outside the qualified benchmark's measurable scope but represents a material risk to recommendation-stage visibility.

What Nebula Genomics Is Winning

Questions This Section Answers

• How strong is Nebula Genomics on Gemini compared with its other tracked platforms?
• Why did Nebula Genomics' rank-one rate rise even as its overall recommendation coverage fell?

Nebula Genomics holds a narrow but meaningful recommendation pocket on Gemini. The brand recorded a 33.77% valid recommendation coverage on that platform, the highest of any tracked platform, alongside a 3.90% rank-one rate and a 3.27 average recommended rank. That is the strongest platform-level recommendation signal in the brand's current profile.

The brand also retained a rank-one rate of 1.24% across all platforms in October 2026, up from 0.80% in July 2026. That gain occurred even as overall coverage, presence, and top-three rates all declined, which suggests the brand's rank-one placements are concentrated in a small number of prompts where it is the clear first choice.

Sentiment is another area of relative strength. The brand's net sentiment score of 0.754 is positive and comparable to much larger competitors, including 23andMe at 0.708 and MyHeritage DNA at 0.784. Only 2 of the brand's 126 mentions carried negative framing.

These wins are real but narrow. The brand does not hold category leadership on any platform, and its strongest platform signal on Gemini sits well below the category leader's performance on the same platform.

Where Nebula Genomics Has the Clearest AI Visibility Gaps

Questions This Section Answers

• Why does Nebula Genomics convert fewer mentions into valid recommendations than AncestryDNA or 23andMe?
• Which platforms show the weakest recommendation coverage for Nebula Genomics?

The clearest gap is recommendation conversion. Nebula Genomics appears in 22.38% of qualified observations but receives a valid recommendation in only 16.52%. That means roughly one in four mentions of the brand does not convert into a recommendation. By comparison, AncestryDNA converts 99.64% presence into 73.18% coverage, and 23andMe converts 97.16% presence into 67.32% coverage. The conversion gap is wider for Nebula Genomics than for the category leaders.

The second gap is top-three placement. Nebula Genomics appears in the top three in just 7.10% of qualified observations, with 40 top-three placements against 93 valid recommendations. That means the brand is being recommended but rarely placed among the first three options. AncestryDNA recorded 411 top-three placements, 23andMe recorded 347, and MyHeritage DNA recorded 280. The brand's top-three rate is closer to Living DNA at 2.66% than to the mid-tier competitors above it.

The third gap is platform coverage. Nebula Genomics recorded no rank-one placements on Perplexity and only a 6.90% valid recommendation coverage there. On Google AI Overviews, the brand recorded a 15.65% valid recommendation coverage and a 0.68% rank-one rate. On ChatGPT, the brand recorded an 8.70% valid recommendation coverage and a 1.45% rank-one rate. The brand's recommendation strength is concentrated on Gemini and Google AI Mode, with weaker signals elsewhere.

The fourth gap is the baseline decline. Nebula Genomics fell from 27.30% valid recommendation coverage in July 2026 to 16.52% in October 2026, a decline of 10.80 percentage points beyond normal variation. The brand declined in each of the three months since the baseline. Raw mention presence fell from 30.30% to 22.38%, a drop of 7.92 percentage points. The decline is broad-based across presence, coverage, and top-three placement.

Biggest Opportunity

Questions This Section Answers

• Which prompts represent the clearest path from mention to recommendation for Nebula Genomics?
• How could Nebula Genomics' whole-genome sequencing positioning support stronger recommendation placement?

The biggest opportunity for Nebula Genomics is to close the gap between its mention presence and its recommendation conversion on the platforms where it already appears. The brand is mentioned in 22.38% of qualified observations but recommended in only 16.52%, and the prompts driving those mentions are concentrated in the Best DNA Testing Kits discovery and evaluation cluster.

The specific opportunity is to strengthen the brand's position in the prompts where it is mentioned but not recommended. Those prompts represent the clearest path from reference to recommendation. The brand's whole-genome sequencing positioning, which appears in the cited source layer, is a differentiator that could support stronger recommendation placement if the public evidence layer made that positioning easier for AI systems to retrieve and synthesize.

The secondary opportunity is to address the factual inconsistency about the brand's operating status. Three critical conflicts between Gemini and Copilot responses directly affect whether the brand is recommended at all. Resolving that inconsistency in the public evidence layer is a prerequisite for stabilizing recommendation-stage visibility.

Competitive Landscape

Questions This Section Answers

• Where does Nebula Genomics rank in the DNA testing kit category by top-three and rank-one rates?
• How does Nebula Genomics' average recommended rank compare with larger competitors like 23andMe and MyHeritage DNA?

AncestryDNA holds dominant recommendation power in the DNA testing kit category, with 23andMe as the strongest challenger and MyHeritage DNA as the third-strongest recommendation-stage brand. Nebula Genomics sits in the lower tier, behind Living DNA and ahead of African Ancestry, CRI Genetics, tellmeGen, and Health Nucleus.

Average recommended rank covers rank-eligible recommendations only.

Nebula Genomics ranks fifth in the category by top-three rate and sixth by valid recommendation coverage. Its rank-one rate of 1.24% is lower than 23andMe's 1.60% but higher than MyHeritage DNA's 0.89% and FamilyTreeDNA's 0.18%, which means the brand is more likely to be the first recommendation when it is recommended than several larger competitors. The gap between its top-three rate and its rank-one rate is narrower than the category leaders, which suggests the brand's recommendation placements are concentrated at the top when they occur.

AI Response Inconsistency Alerts

Questions This Section Answers

• Which AI platforms gave conflicting answers about whether Nebula Genomics is still operating?
• Which sources are driving the shutdown claim about Nebula Genomics in AI responses?

Three critical factual inconsistencies were detected for Nebula Genomics across two AI platforms, Gemini and Copilot. All three conflicts concern whether the brand is still operating, and all three carry high confidence.

The first conflict involves the question "What is the highest rated DNA test kit?" Gemini stated that Nebula Genomics is active and recommended for whole genome sequencing, citing Genomelink, DNA Weekly, and the brand's own blog. Copilot stated that Nebula Genomics shut down in 2025 and that Sequencing.com is the successor, citing Amazon product pages for AncestryDNA and 23andMe. A flagged source on the Copilot side, GuideToGenetics, stated that Nebula Genomics shut down in early 2025 and that the active replacement is Sequencing.com. A flagged source on the Gemini side, KnowYourDNA, referenced Nebula Genomics for whole-genome reads.

The second conflict involves the question "What is the most accurate DNA test kit available?" Gemini stated that Nebula Genomics is a top DNA test kit for whole-genome health analysis and is currently operating, citing Innerbody, Gene Food, and Your DNA Guide. Copilot stated that Nebula Genomics shut down in 2025 and was replaced by DNA Complete, citing KnowYourDNA, Chronos Genomics, and KnowYourDNA again. The same GuideToGenetics source appeared on the Copilot side with the same shutdown claim.

The third conflict involves the question "What is the most accurate DNA test kit?" Gemini stated that Nebula Genomics is an active provider offering 30x whole genome sequencing. Copilot stated that Nebula Genomics shut down in 2025, citing KnowYourDNA, GuideToGenetics, and GenomeTesting.org. The GuideToGenetics source again carried the shutdown claim with a confidence of 0.95.

These conflicts matter because they directly affect whether the brand is recommended at all. When one platform describes the brand as active and another describes it as shut down, the recommendation outcome depends on which platform the buyer uses. The flagged sources suggest the shutdown claim originates from a small number of pages that AI systems are retrieving and synthesizing.

Prompt Evidence

Gemini / Best DNA Testing Kits, Discovery and Evaluation Prompt: "What is the most accurate DNA test kit available?" Result: Gemini recommended Nebula Genomics for whole-genome health analysis and described the brand as currently operating.

Copilot / Best DNA Testing Kits, Discovery and Evaluation Prompt: "What is the most accurate DNA test kit?" Result: Copilot stated that Nebula Genomics shut down in 2025, displacing the brand from the recommendation set entirely.

Google AI Mode / Best DNA Testing Kits, Discovery and Evaluation Prompt: "What is the best DNA ancestry kit to buy?" Result: Nebula Genomics appeared in the response set with a 10.08% valid recommendation coverage on this platform, well below the category leaders.

Perplexity / Best DNA Testing Kits, Discovery and Evaluation Prompt: "What is the most accurate DNA test to take?" Result: Nebula Genomics recorded a 6.90% valid recommendation coverage on Perplexity with no rank-one placements, the weakest platform signal in the brand's profile.

What CiteWorks Studio Would Do Next

Phase 1: AI Visibility Market Discovery Audit Map the specific prompts where Nebula Genomics is mentioned but not recommended, and identify which competitors take the recommendation slot in those responses.

Phase 2: Recommendation Readiness Plan Prioritize the prompts and platforms where the brand's presence-to-recommendation conversion gap is widest, starting with Perplexity and ChatGPT.

Phase 3: Owned Answer Layer Buildout Strengthen the brand's owned pages so that whole-genome sequencing positioning, operating status, and product differentiators are easy for AI systems to retrieve and synthesize.

Phase 4: Citation and Authority Layer Development Address the source pages driving the shutdown claim and build a stronger public evidence layer around the brand's current operating status and product capabilities.

Phase 5: Monthly AI Visibility and Recommendation Tracking Track recommendation coverage, top-three placement, and rank-one rate month over month to measure whether the conversion gap is closing.

Why This Matters

AI presence alone is not enough. Nebula Genomics is mentioned in nearly one in four qualified observations, but it is only recommended in one in six, and it appears in the top three in fewer than one in fourteen. The brand's positive sentiment and narrow rank-one strength show that AI systems can recommend it, but the conversion gap shows that they often do not.

The next move is targeted correction of the prompt, page, and citation layers. The brand's whole-genome sequencing positioning is a genuine differentiator, but it is not converting into recommendation-stage visibility at the rate the category leaders achieve. Closing that gap requires making the brand's operating status, product capabilities, and evidence layer easier for AI systems to retrieve and synthesize.

Core Metrics

Sentiment Score

Questions This Section Answers

• Why can a positive sentiment score overstate a brand's AI visibility position?
• What does Nebula Genomics' sentiment score say alongside its 16.52% recommendation coverage and 7.10% top-three rate?

Sentiment Score = (positive mentions × 1 + neutral mentions × 0 + negative mentions × -1) / total mentions

For Nebula Genomics in October 2026, that calculation is (97 × 1 + 27 × 0 + 2 × -1) / 126, which produces a net sentiment score of 0.754.

This matters because unclassified mention counts are misleading. A brand with 126 mentions could look strong on raw presence alone, but 27 of those mentions were neutral references and 2 carried negative framing. Counting all mentions as wins would overstate the brand's position.

Share of voice is a diagnostic metric, not a business KPI. A positive recommendation, a neutral reference, a cautionary mention, and a competitor-displaced mention are not equal. Nebula Genomics' positive sentiment score shows that when the brand is mentioned, the framing is favorable, but the score does not capture whether the brand was recommended or merely referenced.

Classified sentiment is required before interpreting AI visibility. The brand's 0.754 score places it in positive territory, comparable to much larger competitors, but that score sits alongside a 16.52% recommendation coverage and a 7.10% top-three rate. Sentiment alone does not explain the conversion gap.

Sentiment by Platform

Methodology

1. This report is a benchmark-based analysis of how AI search and chat surfaces present Nebula Genomics in the DNA testing kit category. It is not a client result and does not imply that any remediation has occurred.
2. The reporting month is October 2026, with baseline comparisons drawn from July 2026 and month-over-month comparisons drawn from September 2026.
3. Six AI platforms were tracked: ChatGPT, Copilot, Gemini, Perplexity, Google AI Overviews, and Google AI Mode.
4. The qualified benchmark set contained 563 observations in October 2026, drawn from 800 source prompt-surface observations after qualification.
5. The competitor universe included ten tracked brands: AncestryDNA, 23andMe, MyHeritage DNA, FamilyTreeDNA, Living DNA, Nebula Genomics, African Ancestry, CRI Genetics, tellmeGen, and Health Nucleus.
6. One qualified high-intent cluster was used: Best DNA Testing Kits, Discovery and Evaluation. The pricing and value and multi-brand comparison clusters contained no qualified observations in the current benchmark.
7. Stage 0 extraction retained the query, AI surface, answer, brand outcome, recommendation placement, sentiment, and, where exposed, citations or attributable evidence sources.
8. A mention is any qualified observation in which Nebula Genomics appears in any form, whether recommended or not.
9. A valid recommendation is a qualified observation in which Nebula Genomics receives a recommendation with a rank position between 1 and 10. Neutral, cautionary, and comparison-anchor mentions are not counted as valid recommendations.
10. The unique question count for October 2026 was 467. The public benchmark does not expose a unique prompt count per brand.
11. Brand-level percentages use the 563 qualified observations as the public denominator, not the 800 raw prompts collected.
12. Small-count movement applies to brands with fewer than 10 valid recommendations. Nebula Genomics recorded 93 valid recommendations, so its percentages are not subject to the small-count caveat that applies to tellmeGen, CRI Genetics, and Health Nucleus.

See How AI Is Recommending Your Brand

The public benchmark shows where Nebula Genomics is winning and losing in AI-generated recommendations. A company-level AI visibility audit maps the specific prompts, platforms, competitors, and evidence sources driving those outcomes into a prioritized strategy. It turns the benchmark's view of what changed into an actionable view of why it changed and what to do next.